140 related articles for article (PubMed ID: 29572796)
1. Clinical Correlation of the Histoculture Drug Response Assay for Head and Neck Cancer.
Hoffman RM
Methods Mol Biol; 2018; 1760():83-92. PubMed ID: 29572796
[TBL] [Abstract][Full Text] [Related]
2. Clinical Usefulness of the Histoculture Drug Response Assay for Breast Cancer.
Hoffman RM; Tanino H
Methods Mol Biol; 2018; 1760():93-100. PubMed ID: 29572797
[TBL] [Abstract][Full Text] [Related]
3. Clinical Correlation of the Histoculture Drug Response Assay in Gastrointestinal Cancer.
Hoffman RM
Methods Mol Biol; 2018; 1760():61-72. PubMed ID: 29572794
[TBL] [Abstract][Full Text] [Related]
4. Prospective Clinical Correlation of the Histoculture Drug Response Assay for Ovarian Cancer.
Hoffman RM; Jung PS; Kim MB; Nam JH
Methods Mol Biol; 2018; 1760():73-81. PubMed ID: 29572795
[TBL] [Abstract][Full Text] [Related]
5. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay.
Singh B; Li R; Xu L; Poluri A; Patel S; Shaha AR; Pfister D; Sherman E; Goberdhan A; Hoffman RM; Shah J
Head Neck; 2002 May; 24(5):437-42. PubMed ID: 12001073
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
[TBL] [Abstract][Full Text] [Related]
7. Clinical applications of the histoculture drug response assay.
Furukawa T; Kubota T; Hoffman RM
Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T
Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
[TBL] [Abstract][Full Text] [Related]
9. Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay.
Ariyoshi Y; Shimahara M; Tanigawa N
Oral Oncol; 2003 Oct; 39(7):701-7. PubMed ID: 12907210
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
11. Development of the Histoculture Drug Response Assay (HDRA).
Hoffman RM; Vescio RA
Methods Mol Biol; 2018; 1760():39-48. PubMed ID: 29572792
[TBL] [Abstract][Full Text] [Related]
12. Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer.
Fujita Y; Hiramatsu M; Kawai M; Nishimura H; Miyamoto A; Tanigawa N
Oncol Rep; 2009 Feb; 21(2):499-505. PubMed ID: 19148528
[TBL] [Abstract][Full Text] [Related]
13. Potential of the histoculture drug-response assay to contribute to cancer patient survival.
Kubota T; Sasano N; Abe O; Nakao I; Kawamura E; Saito T; Endo M; Kimura K; Demura H; Sasano H
Clin Cancer Res; 1995 Dec; 1(12):1537-43. PubMed ID: 9815954
[TBL] [Abstract][Full Text] [Related]
14. Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin.
Robbins KT; Connors KM; Storniolo AM; Hanchett C; Hoffman RM
Arch Otolaryngol Head Neck Surg; 1994 Mar; 120(3):288-92. PubMed ID: 8123238
[TBL] [Abstract][Full Text] [Related]
15. [High clinical predictability of histoculture drug response assay (HDRA) for drug-sensitivity of cancer of the digestive organs].
Kubota T; Furukawa T; Kitajima M
Gan To Kagaku Ryoho; 1993 Mar; 20(4):461-6. PubMed ID: 8452384
[TBL] [Abstract][Full Text] [Related]
16. [Chemosensitivity test for gastric carcinoma].
Kubota T
Gan To Kagaku Ryoho; 1997 Feb; 24(4):495-500. PubMed ID: 9063490
[TBL] [Abstract][Full Text] [Related]
17. [Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].
Hirai Y; Yoshimasu T; Oura S; Tamaki T; Ota F; Nakamura R; Shimizu Y; Naito K; Ota M; Miyasaka M; Okamura Y; Nakamura Y; Yasuoka H; Kodama R
Gan To Kagaku Ryoho; 2009 Apr; 36(4):611-4. PubMed ID: 19381033
[TBL] [Abstract][Full Text] [Related]
18. Independence of cytotoxic drug sensitivity profiles and receptor subtype of invasive ductal breast carcinoma demonstrated by the histoculture drug response assay (HDRA).
Kim KY; Chung BW; Yang I; Kim MB; Hoffman RM
Anticancer Res; 2014 Dec; 34(12):7197-201. PubMed ID: 25503149
[TBL] [Abstract][Full Text] [Related]
19. Clinical Usefulness of the Histoculture Drug Response Assay for Prostate Cancer and Benign Prostate Hypertrophy (BPH).
Hoffman RM
Methods Mol Biol; 2018; 1760():101-107. PubMed ID: 29572798
[TBL] [Abstract][Full Text] [Related]
20. Drug response of head and neck tumors in native-state histoculture.
Robbins KT; Varki NM; Storniolo AM; Hoffman H; Hoffman RM
Arch Otolaryngol Head Neck Surg; 1991 Jan; 117(1):83-6. PubMed ID: 1986767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
